Preventing Crohn's recurrence after surgery using stool tests
Part of Digestive system clinical trials.
This trial tests if checking a stool marker (fecal calprotectin) early after surgery can guide treatment with ustekinumab to prevent Crohn's disease from coming back. It's for people who had certain bowel surgery and have at least one risk factor for recurrence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have Crohn's disease.
- You've had surgery to remove part of your small bowel, colon, or both, with no signs of disease left behind.
- The connection where your bowel was reattached must be reachable with a colonoscope.
- You have at least one risk factor: currently smoking, prior bowel surgery, more than 12 inches of small bowel removed, a fistulizing (tunnel-forming) type of Crohn's, or having tried 2 or more biologic drugs before surgery.
- You must be able to take the study drug (ustekinumab) with no medical reasons against it.
- You must live in France and have French healthcare coverage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
This trial tests if combining a drug called ustekinumab with a special liquid diet (semi-exclusive enteral nutrition) is as effective as using only the liquid diet to improve outcomes before Crohn's surgery.
This trial studies whether people with Crohn's disease or ulcerative colitis who are in deep remission can safely reduce their dose of ustekinumab (Stelara) without the disease coming back. It aims to reduce medication burden while keeping patients well.
This study compares two ways to choose biologic (targeted) medicines after Crohn’s surgery to help stop Crohn’s from coming back in the bowel. It may help you avoid or delay repeat inflammation by adjusting treatment based on endoscopy findings.
This study checks whether adding an extra, cross-body “transmural” evaluation (looking at inflammation throughout the bowel) improves care for adults with Crohn’s who are starting or receiving biologic (biotherapy) treatment. It uses close follow-up with stool calprotectin (a marker of gut inflammation) to see if this approach helps control inflammation.
Hear when a new Crohn Disease (CD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.